ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CHRO Chromocell Therapeutics Corporation

3.13
-0.18 (-5.44%)
Mar 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 16,258
Bid Price
Ask Price
News (1)
Day High 3.33

Low
3.0301

52 Week Range

High
6.00

Day Low 3.0301
Company Name Stock Ticker Symbol Market Type
Chromocell Therapeutics Corporation CHRO AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.18 -5.44% 3.13 19:24:56
Open Price Low Price High Price Close Price Prev Close
3.32 3.0301 3.33 3.13 3.31
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
492 16,258 $ 3.22 $ 52,271 - 3.0301 - 6.00
Last Trade Time Type Quantity Stock Price Currency
18:30:00 100 $ 3.13 USD

Chromocell Therapeutics Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 18.05M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Chromocell Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CHRO Message Board. Create One! See More Posts on CHRO Message Board See More Message Board Posts

Historical CHRO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.503.683.03013.4019,983-0.37-10.57%
1 Month4.274.843.03013.7520,085-1.14-26.70%
3 Months6.006.003.03014.1430,098-2.87-47.83%
6 Months6.006.003.03014.1430,098-2.87-47.83%
1 Year6.006.003.03014.1430,098-2.87-47.83%
3 Years6.006.003.03014.1430,098-2.87-47.83%
5 Years6.006.003.03014.1430,098-2.87-47.83%

Chromocell Therapeutics Description

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Your Recent History

Delayed Upgrade Clock